[1] Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, et al. The challenges of primary biliary cholangitis: What is new and what needs to be done[J]. J Autoimmun 2019: 102328.
[2] EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol 2017; 67(1): 145-172.
[3] Wagner M, Fickert P. Drug Therapies for Chronic Cholestatic Liver Diseases[J]. Annu Rev Pharmacol Toxicol 2019.
[4] Joyce SA, Gahan CG. Bile Acid Modifications at the Microbe-Host Interface: Potential for Nutraceutical and Pharmaceutical Interventions in Host Health[J]. Annu Rev Food Sci Technol 2016; 7: 313-333.
[5] Chen ML, Takeda K, Sundrud MS. Emerging roles of bile acids in mucosal immunity and inflammation[J]. Mucosal Immunol 2019; 12(4): 851-861.
[6] Liu Y, Chen K, Li F, et al. Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice[J]. Hepatology 2020; 71(6): 2050-2066.
[7] Friedman ES, Li Y, Shen TD, et al. FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid[J]. Gastroenterology 2018; 155(6): 1741-1752.e1745.
[8] Tang R, Wei Y, Li Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J]. Gut 2018; 67(3): 534-541.
[9] Li B, Selmi C, Tang R, et al. The microbiome and autoimmunity: a paradigm from the gut-liver axis[J]. Cell Mol Immunol 2018; 15(6): 595-609.
[10] Chen W, Wei Y, Xiong A, et al. Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis[J]. Clin Rev Allergy Immunol 2019.
[11] Sjoberg BG, Straniero S, Angelin B, et al. Cholestyramine treatment of healthy humans rapidly induces transient hypertriglyceridemia when treatment is initiated[J]. Am J Physiol Endocrinol Metab 2017; 313(2): E167-e174.
[12] Fuchs CD, Paumgartner G, Mlitz V, et al. Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2(-/-) mice by modulating composition, signalling and excretion of faecal bile acids[J]. Gut 2018; 67(9): 1683-1691.
[13] Polter DE, Gruhl V, Eigenbrodt EH, et al. Beneficial effect of cholestyramine in sclerosing cholangitis[J]. Gastroenterology 1980; 79(2): 326-333.
[14] Xie G, Wang Y, Wang X, et al. Profiling of serum bile acids in a healthy Chinese population using UPLC-MS/MS[J]. J Proteome Res 2015; 14(2): 850-859.
[15] Zhu P, Zhang J, Chen Y, et al. Analysis of human C24 bile acids metabolome in serum and urine based on enzyme digestion of conjugated bile acids and LC-MS determination of unconjugated bile acids[J]. Anal Bioanal Chem 2018; 410(21): 5287-5300.
[16] Zhao L, Ni Y, Su M, et al. High Throughput and Quantitative Measurement of Microbial Metabolome by Gas Chromatography/Mass Spectrometry Using Automated Alkyl Chloroformate Derivatization[J]. Anal Chem 2017; 89(10): 5565-5577.
[17] Segata N, Waldron L, Ballarini A, et al. Metagenomic microbial community profiling using unique clade-specific marker genes[J]. Nat Methods 2012; 9(8): 811-814.
[18] Franzosa EA, McIver LJ, Rahnavard G, et al. Species-level functional profiling of metagenomes and metatranscriptomes[J]. Nat Methods 2018; 15(11): 962-968.
[19] Friedman J, Alm EJ. Inferring correlation networks from genomic survey data[J]. PLoS Comput Biol 2012; 8(9): e1002687.
[20] Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks[J]. Genome Res 2003; 13(11): 2498-2504.
[21] Pinto C, Giordano DM, Maroni L, et al. Role of inflammation and proinflammatory cytokines in cholangiocyte pathophysiology[J]. Biochim Biophys Acta Mol Basis Dis 2018; 1864(4 Pt B): 1270-1278.
[22] Thompson WG. Cholestyramine[J]. Can Med Assoc J 1971; 104(4): 305-309.
[23] Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis[J]. Cell Metab 2009; 10(3): 167-177.
[24] Marzioni M, Alpini G, Saccomanno S, et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis[J]. Gastroenterology 2007; 133(1): 244-255.
[25] Marzioni M, Alpini G, Saccomanno S, et al. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis[J]. Gut 2009; 58(7): 990-997.
[26] Harach T, Pols TW, Nomura M, et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins[J]. Sci Rep 2012; 2: 430.
[27] Beysen C, Murphy EJ, Deines K, et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study[J]. Diabetologia 2012; 55(2): 432-442.
[28] Potthoff MJ, Potts A, He T, et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice[J]. Am J Physiol Gastrointest Liver Physiol 2013; 304(4): G371-380.
[29] Postler TS, Ghosh S. Understanding the Holobiont: How Microbial Metabolites Affect Human Health and Shape the Immune System[J]. Cell Metab 2017; 26(1): 110-130.
[30] Nakamoto N, Sasaki N, Aoki R, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis[J]. Nat Microbiol 2019; 4(3): 492-503.
[31] Liu Y, Wang Y, Ni Y, et al. Gut Microbiome Fermentation Determines the Efficacy of Exercise for Diabetes Prevention[J]. Cell Metab 2020; 31(1): 77-91.e75.
[32] Luu M, Pautz S, Kohl V, et al. The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes[J]. Nat Commun 2019; 10(1): 760.
[33] De Preter V, Machiels K, Joossens M, et al. Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD[J]. Gut 2015; 64(3): 447-458.
[34] Jørgensen JR, Clausen MR, Mortensen PB. Oxidation of short and medium chain C2-C8 fatty acids in Sprague-Dawley rat colonocytes[J]. Gut 1997; 40(3): 400-405.
[35] Coyte KZ, Rakoff-Nahoum S. Understanding Competition and Cooperation within the Mammalian Gut Microbiome[J]. Curr Biol 2019; 29(11): R538-r544.
[36] Chen L, Collij V, Jaeger M, et al. Gut microbial co-abundance networks show specificity in inflammatory bowel disease and obesity[J]. Nat Commun 2020; 11(1): 4018.
[37] Faust K, Sathirapongsasuti JF, Izard J, et al. Microbial co-occurrence relationships in the human microbiome[J]. PLoS Comput Biol 2012; 8(7): e1002606.
[38] Yilmaz B, Juillerat P, Øyås O, et al. Microbial network disturbances in relapsing refractory Crohn's disease[J]. Nat Med 2019; 25(2): 323-336.
[39] Wang J, Zheng J, Shi W, et al. Dysbiosis of maternal and neonatal microbiota associated with gestational diabetes mellitus[J]. Gut 2018; 67(9): 1614-1625.